Cerner Corp. (CERN - Free Report) has deployed a new mobility and communications solution named CareAware Connect for clinicians using smart phone devices. This positive news should further boost investor confidence on the stock, which has already risen 4% since Oct 1.
CareAware Connect is a clinical mobility solution, which allows clinicians to communicate as well as access electronic health record (EHR) data and alerts on their smart phones. It has been initially designed to run on the Apple iPhone. Cerner has successfully set up this new tool for clinicians at Fisher-Titus Medical Center in Norwalk, Ohio, and the NCH Healthcare System in Naples, FL.
Management asserts that CareAware Connect is a fast, easy and smart tool, enabling smooth coordination between medical devices, health care applications and EHR systems. Some of the special features of this advanced mobile solution include voice calls within as well as outside clinical settings, secure messaging amongst caregivers, and review EHR data and alerts on smarphones. Cerner plans to further expand CareAware Connect to physicians and add bar-code enabled workflows in future versions.
Although the new product is expected to accelerate CERN’s top-line growth, we are cognizant of stiff competition in the underlying market. Recently, Cerner’s peer, athenahealth (ATHN - Free Report) launched a new mobile application (app), "Epocrates Bugs + Drugs," which combines cloud-based clinical data with a user-friendly mobile interface.
Moreover, Quality Systems (QSII - Free Report) and ITelagen has launched NextGenAnywhere, a technology that delivers the NextGen Ambulatory EHR to mobile devices. Available for iPad and Android tablet mobile devices, NextGenAnywhere is powered by ITelagen's innovative EHRAnywhere platform to enable physicians the freedom and flexibility to access patient medical data and applications.
Cerner presently has a Zacks Rank #3 (Hold). While we choose to remain on the sidelines regarding CERN, medical stock Cardinal Health, Inc. (CAH - Free Report) carrying a Zacks Rank #1 (Strong Buy), warrants a look.